Albert Einstein College of Medicine, Bronx, NY.
Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD.
Diabetes. 2020 Jun;69(6):1140-1148. doi: 10.2337/db19-1256. Epub 2020 Mar 26.
Hyperglycemia is a potent regulator of endogenous glucose production (EGP). Loss of this "glucose effectiveness" is a major contributor to elevated plasma glucose concentrations in type 2 diabetes (T2D). K channels in the central nervous system have been shown to regulate EGP in humans and rodents. We examined the contribution of central K channels to glucose effectiveness. Under fixed hormonal conditions (studies using a pancreatic clamp), hyperglycemia suppressed EGP by ∼50% in both humans without diabetes and normal Sprague-Dawley rats. By contrast, antagonism of K channels with glyburide significantly reduced the EGP-lowering effect of hyperglycemia in both humans and rats. Furthermore, the effects of glyburide on EGP and gluconeogenic enzymes were abolished in rats by intracerebroventricular administration of the K channel agonist diazoxide. These findings indicate that about half of the suppression of EGP by hyperglycemia is mediated by central K channels. These central mechanisms may offer a novel therapeutic target for improving glycemic control in subjects with T2D.
高血糖是内源性葡萄糖产生 (EGP) 的有效调节剂。在 2 型糖尿病 (T2D) 中,这种“葡萄糖效应”的丧失是导致血浆葡萄糖浓度升高的主要原因。中枢神经系统中的 K 通道已被证明可调节人类和啮齿动物的 EGP。我们研究了中枢 K 通道对葡萄糖效应的贡献。在固定激素条件下(使用胰腺夹进行的研究),高血糖使无糖尿病的人类和正常 Sprague-Dawley 大鼠的 EGP 降低了约 50%。相比之下,用格列本脲拮抗 K 通道显著降低了高血糖对人类和大鼠 EGP 的降低作用。此外,在大鼠中,通过侧脑室给予 K 通道激动剂二氮嗪,格列本脲对 EGP 和糖异生酶的作用被消除。这些发现表明,高血糖对 EGP 的抑制作用约有一半是由中枢 K 通道介导的。这些中枢机制可能为改善 T2D 患者的血糖控制提供一个新的治疗靶点。